MedTrace Logo

Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

NCT00520806 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1161

Last updated 2012-10-30

No results posted yet for this study

Summary

Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure

Conditions

  • Heart Failure, Congestive

Interventions

DRUG

Relaxin

Intravenous infusion for 48 h at 30 ug/kg/day

DRUG

Placebo

Intravenous infusion for 48 h

Sponsors & Collaborators

  • Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

    lead INDUSTRY

Principal Investigators

  • Thomas Severin, MD · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00520806 on ClinicalTrials.gov